Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Annual Earnings
ZVRA·Reported March 11, 2025·After market close
Zevra Therapeutics, Inc. reported Q4 2024 revenue of $12.0M, missed analyst consensus of $16.7M by $4.6M. Diluted EPS came in at $-0.67, missed the $-0.39 consensus by $0.28.
Revenue
$12.0Mmissed by $4.6M
Consensus: $16.7MDiluted EPS
$-0.67missed by $0.28
Consensus: $-0.39
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Zevra Therapeutics, Inc.'s Q4 2024 earnings report.
Zevra Therapeutics, Inc. (ZVRA) reported Q4 2024 earnings on March 11, 2025 after market close.
Zevra Therapeutics, Inc. reported revenue of $12.0M and diluted EPS of $-0.67 for Q4 2024.
Revenue missed the consensus estimate of $16.7M by $4.6M. EPS missed the consensus estimate of $-0.39 by $0.28.
You can read the 10-K periodic report (0001437749-25-007320) directly on SEC EDGAR. The filing index links above go to sec.gov.